Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
Authors
Keywords
-
Journal
Current Neurology and Neuroscience Reports
Volume 12, Issue 5, Pages 592-600
Publisher
Springer Nature
Online
2012-07-11
DOI
10.1007/s11910-012-0291-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
- (2012) Per Soelberg Sørensen et al. Multiple Sclerosis Journal
- Potential Health Care Cost Savings Associated With Early Treatment of Multiple Sclerosis Using Disease-Modifying Therapy
- (2011) Suellen M. Curkendall et al. CLINICAL THERAPEUTICS
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
- (2011) Bhupendra Khatri et al. LANCET NEUROLOGY
- Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study
- (2011) K. Noyes et al. NEUROLOGY
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- (2011) P. W. O'Connor et al. NEUROLOGY
- Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis
- (2011) Ken O’Day et al. JOURNAL OF MEDICAL ECONOMICS
- Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study
- (2011) Bernard Uitdehaag et al. Therapeutic Advances in Neurological Disorders
- Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis
- (2010) Hiangkiat Tan et al. ADVANCES IN THERAPY
- A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type
- (2010) Shekoufeh Nikfar et al. CLINICAL THERAPEUTICS
- Pharmacoeconomic Considerations in the Treatment of Multiple Sclerosis
- (2010) Jessica Sharac et al. DRUGS
- Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial
- (2010) G. C. Ebers et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Improving combination trials for multiple sclerosis
- (2010) Maria Trojano LANCET NEUROLOGY
- Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial
- (2010) Mads Ravnborg et al. LANCET NEUROLOGY
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
- (2010) David B Clifford et al. LANCET NEUROLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Smoking and Disease Progression in Multiple Sclerosis
- (2009) Brian C. Healy et al. ARCHIVES OF NEUROLOGY
- Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis
- (2009) Fotini Pittas et al. JOURNAL OF NEUROLOGY
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
- (2009) G Comi et al. LANCET
- NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
- (2009) Per Soelberg Sorensen et al. LANCET NEUROLOGY
- Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
- (2009) Ludwig Kappos et al. LANCET NEUROLOGY
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
- (2009) Roisín Lonergan et al. Multiple Sclerosis Journal
- Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis
- (2009) R. Zivadinov et al. NEUROLOGY
- Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
- (2009) Ray Gani et al. PHARMACOECONOMICS
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- Smoking is a risk factor for early conversion to clinically definite multiple sclerosis
- (2008) F Di Pauli et al. Multiple Sclerosis Journal
- Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
- (2008) G Kobelt et al. Multiple Sclerosis Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now